絞り込み

16555

広告

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece.

著者 Kousoulakou H , Hatzikou M , Baroutsou V , Yfantopoulos J
Cost Eff Resour Alloc.2017 ; 15():19.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (104view , 0users)

Full Text Sources

This study was designed to assess the cost-effectiveness of vildagliptin versus glimepiride as add-on to metformin in the management of type 2 diabetes mellitus (T2DM) patients in the Greek healthcare setting.
PMID: 28904527 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード